140 related articles for article (PubMed ID: 23543917)
1. RNA blood levels of osteopontin splice variants are cancer markers.
Hartung F; Weber GF
Springerplus; 2013 Dec; 2(1):110. PubMed ID: 23543917
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of Osteopontin splice variants in cancer.
An Y; Fnu G; Xie C; Weber GF
BMC Cancer; 2023 Apr; 23(1):373. PubMed ID: 37095438
[TBL] [Abstract][Full Text] [Related]
3. Osteopontin-c is a selective marker of breast cancer.
Mirza M; Shaughnessy E; Hurley JK; Vanpatten KA; Pestano GA; He B; Weber GF
Int J Cancer; 2008 Feb; 122(4):889-97. PubMed ID: 17960616
[TBL] [Abstract][Full Text] [Related]
4. Osteopontin is a marker for cancer aggressiveness and patient survival.
Weber GF; Lett GS; Haubein NC
Br J Cancer; 2010 Sep; 103(6):861-9. PubMed ID: 20823889
[TBL] [Abstract][Full Text] [Related]
5. Categorical meta-analysis of Osteopontin as a clinical cancer marker.
Weber GF; Lett GS; Haubein NC
Oncol Rep; 2011 Feb; 25(2):433-41. PubMed ID: 21165579
[TBL] [Abstract][Full Text] [Related]
6. Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence.
Ortiz-Martínez F; Perez-Balaguer A; Ciprián D; Andrés L; Ponce J; Adrover E; Sánchez-Payá J; Aranda FI; Lerma E; Peiró G
Hum Pathol; 2014 Mar; 45(3):504-12. PubMed ID: 24440093
[TBL] [Abstract][Full Text] [Related]
7. Osteopontin-4 and Osteopontin-5 splice variants are expressed in several tumor cell lines.
Silva GR; Mattos DS; Bastos ACF; Viana BPPB; Brum MCM; Ferreira LB; Gimba ERP
Mol Biol Rep; 2020 Oct; 47(10):8339-8345. PubMed ID: 33006711
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of mRNA levels of osteopontin splice variants in soft tissue sarcoma patients.
Hahnel A; Wichmann H; Greither T; Kappler M; Würl P; Kotzsch M; Taubert H; Vordermark D; Bache M
BMC Cancer; 2012 Apr; 12():131. PubMed ID: 22471890
[TBL] [Abstract][Full Text] [Related]
9. Osteopontin Regulates VEGFA and ICAM-1 mRNA Expression in Breast Carcinoma.
Ortiz-Martínez F; Sanmartín E; Pomares-Navarro E; Pérez-Balaguer A; Andrés L; Sánchez-Payá J; Aranda FI; Lerma E; Peiró G
Am J Clin Pathol; 2015 Jun; 143(6):812-22. PubMed ID: 25972323
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Osteopontin Splice Variant-c Expression in Breast Cancers: A Meta-Analysis.
Hao C; Wang Z; Gu Y; Jiang WG; Cheng S
Biomed Res Int; 2016; 2016():7310694. PubMed ID: 27462610
[TBL] [Abstract][Full Text] [Related]
11. An osteopontin splice variant induces anchorage independence in human breast cancer cells.
He B; Mirza M; Weber GF
Oncogene; 2006 Apr; 25(15):2192-202. PubMed ID: 16288209
[TBL] [Abstract][Full Text] [Related]
12. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies.
Coppola D; Szabo M; Boulware D; Muraca P; Alsarraj M; Chambers AF; Yeatman TJ
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):184-90. PubMed ID: 14734468
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer risk in premalignant lesions: osteopontin splice variants indicate prognosis.
Walaszek K; Lower EE; Ziolkowski P; Weber GF
Br J Cancer; 2018 Nov; 119(10):1259-1266. PubMed ID: 30353046
[TBL] [Abstract][Full Text] [Related]
14. Osteopontin as a potential diagnostic biomarker for ovarian cancer.
Kim JH; Skates SJ; Uede T; Wong KK; Schorge JO; Feltmate CM; Berkowitz RS; Cramer DW; Mok SC
JAMA; 2002 Apr; 287(13):1671-9. PubMed ID: 11926891
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of osteopontin in patients with triple-negative breast cancer.
Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J
Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545
[TBL] [Abstract][Full Text] [Related]
16. Assessing SPP1/Osteopontin (OPN) Splice Variants and Their Association to Nonmelanoma Skin Cancer by Absolute Quantification: Identification of OPN-5 Subvariants and Their Protein Coding Potential.
Chou CF; Huang CC; Bin Dabil N; Chang PL
Cancer Invest; 2021; 39(6-7):559-570. PubMed ID: 34043476
[TBL] [Abstract][Full Text] [Related]
17. Microcalcifications of breast cancer and atypical cystic lobules associated with infiltration of foam cells expressing osteopontin.
Oyama T; Sano T; Hikino T; Xue Q; Iijima K; Nakajima T; Koerner F
Virchows Arch; 2002 Mar; 440(3):267-73. PubMed ID: 11889596
[TBL] [Abstract][Full Text] [Related]
18. [Over-expression of osteopontin in non-small cell lung cancers: its clinical significance].
Hu Z; Xiao T; Lin DM; Guo SP; Zhang ZQ; Di XB; Cheng SJ; Gao YN
Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):591-5. PubMed ID: 18210878
[TBL] [Abstract][Full Text] [Related]
19. Nuclear osteopontin-c is a prognostic breast cancer marker.
Zduniak K; Ziolkowski P; Ahlin C; Agrawal A; Agrawal S; Blomqvist C; Fjällskog ML; Weber GF
Br J Cancer; 2015 Feb; 112(4):729-38. PubMed ID: 25625274
[TBL] [Abstract][Full Text] [Related]
20. An osteopontin promoter polymorphism is associated with aggressiveness in breast cancer.
Ramchandani D; Weber GF
Oncol Rep; 2013 Oct; 30(4):1860-8. PubMed ID: 23900428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
